3240 Bayshore Boulevard
United States - Map
Fax: 415 330 2444
Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; and xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, fine lines, and laxity. In addition, the company offers GenesisPlus system, a laser product for use in the temporary increase of clear nails in patients with onychomycosis, as well as for the treatment of fine wrinkles, diffuse redness, and rosacea; solera console platform, including Opus and Titan consoles; and CoolGlide systems, as well as provides myQ, a third-party sourced system for the Japanese market. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal and vascular treatments; Pearl and Pearl Fractional hand pieces; dermal filler products; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, primary care physicians, family practitioners, podiatrists, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.
|Cutera, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 6; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Kevin P. Connors ,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Ronald J. Santilli ,
Chief Financial Officer and Exec. VP of Fin. & Admin.
|Mr. Rajesh Madan ,
VP of Fin. & Legal
|Mr. Bradley Renton Ph.D.,
VP of Regulatory & Medical Affairs and Compliance Officer
|Mr. Jonathan Pearson ,
Exec. VP of Marketing & Clinical Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|